Aurinia Pharmaceuticals Inc.
(NASDAQ : AUPH)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
100% secure: your email is never shared, and you may opt out at any time.
Loading AUPH News...
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc.
-0.04%68.550.9%$505.54m
AMGNAmgen Inc.
0.37%163.321.1%$461.64m
BIIBBiogen Inc.
-1.94%271.211.2%$423.43m
CELGCelgene Corporation
0.07%124.051.2%$383.45m
REGNRegeneron Pharmaceuticals, Inc.
5.97%388.492.7%$332.95m
ALXNAlexion Pharmaceuticals, Inc.
0.69%127.781.9%$250.96m
INCYIncyte Corporation
0.09%124.282.6%$247.36m
VRTXVertex Pharmaceuticals Incorporated
0.75%118.301.9%$235.75m
ILMNIllumina, Inc.
0.61%184.863.5%$200.54m
TSROTESARO, Inc.
0.67%147.5914.7%$130.72m
NBIXNeurocrine Biosciences, Inc.
-0.36%53.405.3%$114.24m
BMRNBioMarin Pharmaceutical Inc.
-0.40%95.884.5%$113.09m
KITEKite Pharma, Inc.
-0.68%82.0816.6%$94.29m
AAgilent Technologies, Inc.
-0.70%55.041.5%$93.33m
SRPTSarepta Therapeutics, Inc.
4.44%36.2619.8%$82.73m

Company Profile

Aurinia Pharmaceuticals, Inc. operates as a biopharmaceutical company. It focuses on discovering and developing immunomodulating therapeutics. The company's pipeline includes voclosporin for the treatment of lupus nephritis. Aurinia Pharmaceuticals was founded by Robert Foster, Richard Glickman and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada.